Home/Filings/4/0001415889-23-006365
4//SEC Filing

Avat Xavier 4

Accession 0001415889-23-006365

CIK 0001133869other

Filed

Apr 6, 8:00 PM ET

Accepted

Apr 7, 5:00 PM ET

Size

10.7 KB

Accession

0001415889-23-006365

Insider Transaction Report

Form 4
Period: 2023-03-28
Avat Xavier
CHIEF BUSINESS OFFICER
Transactions
  • Tax Payment

    Common Stock

    2023-04-05$4.19/sh70,019$293,38014,772 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-04-0584,7910 total
    Exercise: $3.46Exp: 2023-07-06Common Stock (84,791 underlying)
  • Sale

    Common Stock

    2023-03-28$4.06/sh3,000$12,1800 total
  • Exercise/Conversion

    Common Stock

    2023-04-05$3.46/sh+84,791$293,37784,791 total
Footnotes (3)
  • [F1]Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on April 5, 2023 of $4.19.
  • [F2]The shares vested 1/48th of the first day of each month, commencing June 1, 2022.
  • [F3]The option expires 90 days following the termination of Mr. Avat's employment with the Company. Mr. Avat's employment terminated on April 7, 2023. While the box indicating that Mr. Avat is no longer subject to Section 16 has been checked, Mr. Avat remains subject to Section 16 through such date.

Issuer

CAPRICOR THERAPEUTICS, INC.

CIK 0001133869

Entity typeother

Related Parties

1
  • filerCIK 0001931345

Filing Metadata

Form type
4
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 5:00 PM ET
Size
10.7 KB